Oxytocin Receptor Antagonist

Oxytocin Receptor Antagonists (33):

Cat. No.	Product Name	Effect	Purity

HY-108677

L-368,899 hydrochloride	Antagonist	99.97%
L-368,899 hydrochloride is a potent, selective, orally bioavailable, non-peptide oxytocin receptor antagonist, with IC₅₀s of 8.9 nM and 26 nM for rat uterus and human uterus oxytocin receptor, respectively. L-368,899 hydrochloride used as a tocolytic agent.

HY-17572

Atosiban	Antagonist	99.44%
Atosiban (RW22164; RWJ22164) is a nonapeptide competitive vasopressin/oxytocin receptor antagonist, and is a desamino-oxytocin analogue. Atosiban is the main tocolytic agent and has the potential for spontaneous preterm labor research.

HY-16741

Erlosiban	Antagonist
Erlosiban (OBE001) is an orally active non-peptide type oxytocin receptor antagonist. Erlosiban inhibits the increase of intracellular calcium concentration, thereby reducing uterine smooth muscle contraction. Erlosiban can be used for research on premature birth and to improve embryo implantation and pregnancy rate in assisted reproductive technology (AR).

HY-129791

L-367773	Antagonist
L-367773 is an orally active, selective oxytocin receptor antagonist, with K_i values of 26 nM and 61 nM for rat uterine oxytocin receptor and human uterine oxytocin receptor, respectively. L-367773 inhibits Oxytocin-stimulated uterine contractions.

HY-15023

Cligosiban	Antagonist	99.95%
Cligosiban (PF-3274167) is an orally active, highly selective, and centrally permeable oxytocin receptor antagonist with good pharmacokinetics in rats and can inhibit physiological ejaculation in rodents^[1][2].

HY-17572A

Atosiban acetate	Antagonist	99.76%
Atosiban acetate (RW22164 acetate;RWJ22164 acetate) is a nonapeptide competitive vasopressin/oxytocin receptor antagonist, and is a desamino-oxytocin analogue. Atosiban is the main tocolytic agent and has the potential for spontaneous preterm labor research.

HY-15010

L-371,257	Antagonist	99.34%
L-371,257 is an orally bioavailable, non-blood-brain barrier penetrant, selective and competitive antagonist of oxytocin receptor (pA2=8.4) with high affinity at both the oxytocin receptor (K_i=19 nM) and vasopressin V1a receptor (K_i=3.7 nM).

HY-14778

Retosiban	Antagonist	98.95%
Retosiban (GSK221149A) is a potent, selective, and orally active oxytocin receptor antagonist (K_i (hOT) = 0.65 nM, K_i (rOT) = 4.1 nM) with no detectable agonist activity. Retosiban has nanomolar affinity for the oxytocin receptor with >1400-fold selectivity over the closely related vasopressin receptors. Retosiban inhibits spontaneous and induces uterine contractions. Retosiban can be studied in research for preterm labour.

HY-W587861

5β-Dihydroprogesterone	Antagonist	99.94%
5β-Dihydroprogesterone (5βDHP) is the metabolite of Progesterone (HY-N0437). 5β-Dihydroprogesterone binds to oxytocin receptor, reduces the Oxytocin (HY-17571)-induced calcium signal transduction, thereby exhibiting the tocolytic activity.

HY-128351

SHR1653	Antagonist	99.58%
SHR1653 is a highly potent, selective and brain penetrated oxytocin receptor (OTR) antagonist, with an IC₅₀ of 15 nM for hOTR.

HY-15011

L-372662	Antagonist	99.24%
L-372662 is a potent and orally active non-peptide oxytocin antagonist with a K_i value of 4.8. The K_d value of L-372662 for wild-type hOTR and [A318G]OTR is 5.8 nM and 73 nM. L-372662 shows selectivity to OTR:V_1aR.

HY-15015

OT-R antagonist 1	Antagonist	≥98.0%
OT-R antagonist 1 is a new potent and selective nonpeptide low molecular weight OT-R antagonist.

HY-15015A

OT-R antagonist 2	Antagonist	99.86%
OT-R antagonist 2 is a nonpeptide low molecular weight OT-R antagonist.

HY-P4895

(d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin	Antagonist	99.20%
(d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin (OVT) is an oxytocin receptor antagonist. (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin can be used for the research of neurological disease.

HY-14778A

(S)-Retosiban	Antagonist	99.12%
(S)-Retosiban is the isomer of Retosiban (HY-14778), and can be used as an experimental control. Retosiban (GSK221149A) is a potent and selective oxytocin antagonist with a K_i of 0.65 nM.

HY-105018

Epelsiban	Antagonist
Epelsiban (GSK 557296) is a potent, selective and orally bioavailable oxytocin receptor antagonist, with a pK_i of 9.9 for human oxytocin receptor.

HY-15007

L 366509	Antagonist
L 366509 is a spiroindenylpiperidine camphorsulfonamide oxytocin (OT) antagonist. Modifications led to a new series of o-tolylpiperazine (TP) camphorsulfonamides, exhibiting high affinity for OT receptors and selectivity over arginine vasopressin receptors. Notably, compound 7 (L-368,899) showed excellent OT receptor affinity, potency in inhibiting OT-stimulated uterine contractions, good aqueous solubility, and oral bioavailability in multiple species. Compound 7 has entered clinical testing as an oral and intravenous tocolytic agent. Molecular modeling suggests the TP camphorsulfonamide structure mimics the D-AA2-Ile3 dipeptide, crucial in potent OT antagonists.

HY-103649

OT antagonist 3	Antagonist
OT antagonist 3 is an oxytocin (OT) antagonist extracted from patent WO2007017752A1.

HY-P3516

Barusiban	Antagonist
Barusiban (FE-200440) is an oxytocin receptor (OT-R) antagonist (K_i=0.8 nM), inhibits OT-induced contraction. Barusiban can be used in preterm labor (PTL), in vitro fertilisation (IVF) and infertility research.

HY-103652

OT antagonist 3 analog	Antagonist
OT antagonist 3 analog is an analog of OT antagonist 3.

Name
Email *

	Sorry, but the email address you supplied was invalid.